NasdaqGM:APGEBiotechs
Assessing Apogee Therapeutics (APGE) Valuation After Stephens Highlights APG777’s Potential in Atopic Dermatitis
Stephens just kicked off coverage of Apogee Therapeutics (APGE) after highlighting fresh data around its lead drug APG777 in atopic dermatitis, a move that shines a brighter light on the company’s long term pipeline story.
See our latest analysis for Apogee Therapeutics.
That backdrop helps explain why investors have been leaning in, with Apogee’s 30 day share price return at 21.18 percent, a powerful 90 day share price return of 111.74 percent, and a 1 year total shareholder return of 62.13...